Dr Rafael Fonseca presents an overview of recent updates in the treatment of multiple myeloma and discusses strategies for incorporating the evidence into clinical practice.
EP. 1: Quadruplet vs Triplet Regimens in Transplant-Eligible MM: Choosing the Optimal Frontline Regimen
Dr Rafael Fonseca, MD, provides insight on the evidence around quadruplet versus triplet therapies in patients with newly diagnosed, transplant-eligible multiple myeloma, and how to select the appropriate treatment regimen for this patient population.
EP. 2: Depth of Response and Treatment Duration in Newly Diagnosed MM
Depth of response and treatment duration in patients with newly diagnosed MM are discussed by Dr Fonseca.
EP. 3: MAIA Trial and Selecting Patients for Triplet Regimens in Transplant-Ineligible MM
Rafael Fonseca, MD reviews the MAIA clinical trial and strategies for choosing the appropriate patients with transplant-ineligible newly diagnosed MM.
EP. 4: Treatment Strategies for Frail Patients and Patients with High-Risk Multiple Myeloma
Dr Fonseca discusses approaches for treating frail patients with multiple myeloma and those with high-risk disease.
EP. 5: Utilizing Daratumumab in the Frontline Setting Versus in Later Lines in MM
Daratumumab effectiveness is evaluated as a frontline treatment approach versus in later lines of therapy in patients with multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512